-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Brand | Therapeutic category |
|---|---|
|
Circadin |
Hormonal hypnotic sedative |
|
Eltroxin |
Thyroid hormone replacement |
|
Maltofer |
Iron supplement |
|
Marcaine |
Regional and spinal anaesthetic |
|
Xylocaine |
Regional anaesthetic |
0
Products
Launched
Launched
(2022: 8)
Product
Recalls
Recalls
(2022: Nil)
0
%
Average Staff
Turnover
Turnover
(2022: 12%)
Work-related
Facilities
Facilities
(2022: Nil)
30
Sales
Representatives
Representatives
(2022: 83)
200
Permanent
Employees
Employees
(June 2022: 563)
| Revenue |
2023 R’million |
2022 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
5 827 |
5 519 |
6 |
|
Regional Brands |
5 150 |
4 824 |
7 |
|
Sterile Focus Brands |
677 |
695 |
(3) |
|
Manufacturing – FDF |
727 |
645 |
13 |
|
Total |
6 554 |
6 164 |
6 |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 84
- Australasia 16
Revenue by segment (%)
- Regional Brands 79
- Sterile Focus Brands 10
- Manufacturing - FDF 11
- The Australia and New Zealand OTC market was valued at AUD5,4 billion June 2023 and grew 14,1% driven by glucose monitors, skin emollients and protectives, and dietetic agents.
- The total pharmaceutical segment excluding the grocery channel grew 14,1% June 2023.
Source: IQVIA June 2023.
